Clevidipine

Dihydropyridine Calcium Channel Blocker — CARDIOVASCULAR SYSTEM

Key facts

Clevidipine is an ofp drug in the Dihydropyridine Calcium Channel Blocker class catalogued in DrugCentral. It was first approved by the FDA in 2008. Its mechanism of action is classified as Calcium Channel Antagonists. DrugCentral lists 2 molecular targets, including CACNA1C and CACNA1D. Recorded indications include Hypertensive disorder.

• Approval status: ofp (first approved 2008 by the FDA).
• Drug class: Dihydropyridine Calcium Channel Blocker.
• Mechanism of action: Calcium Channel Antagonists.
• Molecular targets: CACNA1C and CACNA1D (2 listed in DrugCentral).
• Indications: Hypertensive disorder.
• ATC code: C08CA16 (Dihydropyridine derivatives).
• Molecular formula: C21H23Cl2NO6; molecular weight 456.32 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Hypertensive disorder

Contraindications (7)

• Heart failure
• Hypertriglyceridemia
• Low blood pressure
• Minimal change disease
• Pancreatitis
• Severe Aortic Valve Stenosis
• Tachyarrhythmia

Mechanism & targets

• Mechanism of action (MoA): Calcium Channel Antagonists
• Established pharmacologic class: Dihydropyridine Calcium Channel Blocker

Molecular targets (2)

Target	Gene	Action	Activity
Voltage-dependent L-type calcium channel subunit alpha-1C	CACNA1C	blocker	—
Voltage-dependent L-type calcium channel subunit alpha-1D	CACNA1D	blocker	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2008-08-01	FDA	—	MEDICINES CO

ATC classification

ATC code	Therapeutic hierarchy
C08CA16	CARDIOVASCULAR SYSTEM › CALCIUM CHANNEL BLOCKERS › SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS › Dihydropyridine derivatives

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Ventilation perfusion mismatch	186.9

Chemical structure

• Molecular formula: C₂₁H₂₃Cl₂NO₆
• Molecular weight: 456.32 g/mol
• CAS number: 167221-71-8
• InChIKey: KPBZROQVTHLCDU-UHFFFAOYSA-N
• PubChem CID: 153994

CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Clevidipine used for?

DrugCentral lists the following indications for Clevidipine: Hypertensive disorder.

How does Clevidipine work?

Clevidipine is classified as Calcium Channel Antagonists; its molecular targets in DrugCentral include CACNA1C (blocker) and CACNA1D (blocker).

When was Clevidipine first approved?

Clevidipine was first approved by the FDA in 2008.

What drug class does Clevidipine belong to?

Clevidipine is in the Dihydropyridine Calcium Channel Blocker class.

What is the chemical formula of Clevidipine?

Clevidipine has the molecular formula C21H23Cl2NO6 and a molecular weight of 456.32 g/mol.

Sources

• DrugCentral drug card 674 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1237132 — compound record and bioactivity
• PubChem CID 153994 — chemical identifiers
• DrugBank DB04920 — drug record
• FDA UNII 19O2GP3B7Q — substance identity
• DailyMed: FDA labels for Clevidipine — current prescribing information (label search)
• UniProt Q13936 (CACNA1C) — target protein
• UniProt Q01668 (CACNA1D) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.